Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models: APP Mutations
APPSw

Posted 7 June 2005

General Information

Transgene: The Swedish familial AD double mutation (SFAD, K670N, M671L substitutions) was introduced by site-directed mutagenesis into cDNA encoding h βAPP751. The Thy-1.2-hAPP751SFAD transgene was generated by insertion of the 2.4 kb hAPP751 SFAD cDNA fragment into the XhoI site of an expression vector containing mouse Thy1.2 glycoprotein gene and promoter. The 1.5 kb BanI-XhoI fragment encompassing exons 2 and 4 was replaced by the XhoI cloning site. Vector-free linear fragments, carrying Thy1-huAPP751SFAD were microinjected into pronuclei of B6D2F1 zygotes. After microinjection, viable zygotes were implanted into the oviducts of pseudopregnant foster mothers. Transgenic founders were crossed to C57BL/6 to establish lines.

Mutation: Human APP K670N, M671L

Promoter: mThy1.2

Origin: (C57BL/6, DBA/2) zygotes

Phenotype

Neuropathological analysis:

Amyloidosis in the 2nd year of life: Levels of Aβ lower than 1ng/mg wet brain at 12 month. At 24 months, presence of congophilic plaques in cortex and hippocampus, Aβ40 levels of about 200ng/mg wet brain measured after urea extraction, Aβ42 levels measured in the same conditions 10 fold lower - Amyloidosis 4X more prominent in females than males.

Availability

Laurence Ozmen
F. Hoffmann-La Roche AG
Building 69/440 Grenzacherstr 124, CH-4070
Basel, Switzerland
Phone: +41 61 6870248
Fax: +41 61 688 4575
Email: Laurence.ozmen@roche.com

Reference

Primary:

J.G. Richards, G.A. Higgins, A.M. Ouagazzal, L. Ozmen, J.N. Kew, B. Bohrmann, P. Malherbe, M. Brockhaus, H. Loetscher, C. Czech, G. Huber, H. Bluethmann, H. Jacobsen and J.A. Kemp. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation, J. Neurosci. 23:8989-9003, 2003. Abstract.

Associated:

von Kienlin M, Künnecke B, Metzger F, Steiner G, J. Richards G, Ozmen L, Jacobsen H, Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiology of Dis. 18(1):32-39, 2005. Abstract.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad